Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, Inc. (NASDAQ: MDXG) announced decisive actions aimed at stabilizing its operations and fostering growth. The company filed an investor presentation for its 2022 Annual Meeting on June 7, 2022, emphasizing a strategy for long-term value creation. MiMedx reported its third consecutive quarter of double-digit growth in Advanced Wound Care & Surgical Recovery products. The Board of Directors has been entirely reconstituted since 2019, implementing 70 corporate governance reforms. Shareholders are encouraged to vote for director nominees on the WHITE proxy card.
Prescience Point Capital Management, owning 6.7% of MiMedx Group (MDXG), expressed disappointment over the Board's disinformation tactics regarding shareholder discontent. Ahead of the June 7, 2022, annual meeting, Prescience Point claims multiple shareholders share concerns about management's actions and executive compensation. They intend to withhold votes against Board members Phyllis Gardner and James Bierman, criticizing the Board's governance and executive stock awards while calling for transparency from the management about shareholder feedback.
MiMedx Group, Inc. (NASDAQ: MDXG) has urged shareholders to vote in favor of its director nominees, James L. Bierman and Phyllis Gardner, during the upcoming Annual Meeting on June 7, 2022. The company highlights its successful execution of a transformation strategy under CEO Tim Wright, overcoming past litigation and accounting issues. MiMedx recorded its third consecutive quarter of double-digit revenue growth and is poised to advance its Knee Osteoarthritis clinical trial program, which has significant revenue potential. The Board emphasizes ongoing governance reforms and a commitment to enhancing shareholder value.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to vote "FOR" directors Dr. Phyllis Gardner and James L. Bierman against accusations from Prescience Point Capital Management. The company highlights its improved governance and ongoing transformation since June 2019, reporting three consecutive quarters of double-digit growth. MIMEDX emphasizes a long-term strategy focusing on sustainable growth, while expressing concerns about Prescience Point's potential short-term motivations and history of destabilizing efforts. The Annual Meeting of Shareholders is scheduled for June 7, 2022.
Prescience Point Capital Management, owning approximately 6.7% of MiMedx Group's stock (MDXG), intends to WITHHOLD votes against Directors Phyllis Gardner and James Bierman at the June 7, 2022, Annual Meeting. The firm criticizes the Board for poor governance, excessive executive compensation, and mismanaged clinical trials that caused a 60% share price drop. Prescience believes MDXG has potential in regenerative medicine, citing promising results for its Amniofix product, but emphasizes the need for accountability and better communication from management to enhance shareholder value.
Marietta, Ga., May 5, 2022 - MiMedx Group (Nasdaq: MDXG) announced participation in two upcoming investor conferences. The Bank of America Securities 2022 Healthcare Conference will feature a fireside chat on May 10 at 12:15 PM PT / 3:15 PM ET, accessible via webcast. The H.C. Wainwright Global Investment Conference will occur on May 24 at 10:00 AM ET, also available via webcast.
MiMedx Group reported first quarter 2022 net sales of $58.9 million, reflecting a 1.8% decline from the prior year. However, the continuing portfolio of tissue and cord products achieved a 13% year-over-year growth.
The company reported a net loss of $10.5 million, worsening from a net loss of $8.4 million in the previous year. The gross profit margin stood at 83.1%, slightly down from 83.9% year-over-year.
MiMedx maintained its 2022 sales outlook, expecting growth of 11% to 14% for its Advanced Wound Care products.
MIMEDX Group, Inc. (NASDAQ: MDXG) has responded to Prescience Point Capital's Schedule 13D filing, urging shareholders to support its Board of Directors. The Company emphasizes its commitment to governance, citing 46 engagements with Prescience Point since June 2019. Allegations against the Board, including attempts by Mr. Asbahi to replace directors, are rejected. The Board asserts its dedication to enhancing shareholder value through strategic initiatives in the placental biologics market. Shareholders are encouraged to vote for the Board's nominees in the upcoming Annual Meeting on June 7, 2022.
MiMedx Group, Inc. (Nasdaq: MDXG) will announce its first-quarter financial results on May 3, 2022, after market close. Senior management will review these results in a conference call on May 4, 2022, at 8:30 a.m. Eastern Time. MiMedx specializes in placental tissue allografts for treating chronic wounds and musculoskeletal conditions, employing proprietary methods like the PURION® process. Since inception, over two million allografts have been distributed.
MiMedx Group, Inc. (MDXG) will sponsor a lunch symposium at the Symposium on Advanced Wound Care from April 6-10, 2022, in Phoenix, Arizona. The symposium will showcase data on the effectiveness of EPIFIX in treating chronic wounds, emphasizing its role in reducing amputations in diabetic ulcers. The company will also present three poster abstracts on its PURION® processed allografts. These efforts aim to improve treatment standards for diabetic ulcer patients and highlight the cost-effectiveness of advanced wound care strategies.